Summit Therapeutics plc (NASDAQ: SMMT), formerly known as Summit Corporation plc, was founded in 2003 and changed to its current name in February 2015,Headquartered in the UKAbingdon,76 full-time employeesBiopharmaceutical Company, focusing on the discovery, development and commercialization of new drugs for treating rare diseases and infectious diseases in the UK and North America.
The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/smmt.html
Summit Therapeutics (SMMT)
Summit Therapeutics plc is carrying out a clinical plan for genetic disease Duchenne muscular dystrophy (DMD) and infectious disease caused by clostridium (CDI).The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/smmt.html
SMMT focuses on the research and correlation of related diseases (dwarfism, dwarfism) caused by muscular dystrophy (DMD) gene mutationResearch and development of therapeutic drugsThe two main strategic directions of the company are: research and treatment of Duchenne muscular dystrophy (a fatal genetic muscular atrophy disease) and infectious diseases caused by clostridium.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/smmt.html
The first DMD product candidate drug of Summit Therapeutics is ezutromid, an oral small molecule, which is in phase II clinical trial;The preferred candidate product for CDI is ridinilazole, a small molecule antibiotic for oral administration, which has completed the Phase II clinical trial.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/smmt.html
Summit Therapeutics has established a strategic alliance with Oxford University to develop muscle dystrophy protein regulators.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/smmt.html
Summit Therapeutics (SMMT) US equity investment
Summit Therapeutics plc (NASDAQ: SMMT) was listed on the NASDAQ Stock Exchange on March 5, 2015, with an issue price of $9.9/common stock.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/smmt.html
In May 2024, by opening an account at American Stock House and merging 10000 Hong Kong dollars (HKD) into Long Bridge, you can get a lifetime free commission of [Hong Kong shares+American shares], and can also get up to 1100 Hong Kong dollars of stock certificates+an additional 88 yuanJD.COMCard (exclusive)+RMB 100 rebate (exclusive).Exclusive to American Stock House customers.Click to view details!
The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/smmt.htmlThe article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/smmt.html
two hundred and forty-nine million three hundred and forty-two thousand five hundred and nineteen
WeChat official account: Encyclopedia of US and Hong Kong stocks
WeChat search: mggbkqs
mggbkqs
This article is written byOriginated by American Stock HousePublished on April 19, 2015 at 22:36:12
Original articles of American Stock House,Unauthorized reproduction is strictly prohibited。This article and all articles on this website are intended for information dissemination and sharing, and do not constitute an invitation, solicitation, suggestion, opinion or any guarantee for any securities, financial products or instruments. American Stock House does not endorse any companies, securities firms or financial products.There are risks in investment. Customers should weigh the risks they can bear and make investment judgments independently. If you have any questions, please consult independent professionals.Disclaimer